Skip to main content
 
 

DPP HIV-Syphilis receives CLIA Waiver: The First & Only FDA Approved, CLIA Waived* HIV-Syphilis Rapid Test

*CLIA Waived for fingerstick whole blood

 

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

 
 

Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK® Assay at Chembio Diagnostics Malaysia Facility

1
1

Announcing the receipt of CLIA Waiver for DPP HIV-Syphilis. Contact your local Chembio Representative for more information

CLIA Waved Badge

Upcoming Events:

NACCHO 360, Booth #429

July 14-18, 2025
Anaheim, CA

 

STI World Congress, Booth #E3

July 26-30, 2025
Montreal, Canada

 

ADLM Clinical Lab Expo, Booth #4222

July 27-31, 2025
Chicago, IL

National Conference on Correctional Health Care 2025, Booth #315

November 1-5, 2025
Baltimore, MD

Stay up to date with our latest news.

Chembio

FDA Awards Breakthrough Device Status to the SURE CHECK® HIV Self-Test

Medford N.Y USA/Strasbourg France – June 17, 2025 – Chembio Diagnostic Systems, Inc., a subsidiary…
Chembio

Chembio Diagnostics Inc. receives a grant for Development of a DPP Congenital Syphilis Assay

Chembio Diagnostics Inc., a subsidiary of Biosynex, receives a grant  for Development of a DPP…
Bio Synex Logo
Chembio

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG,…
About Us

We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.

Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.

Our Core Values: “RAPID”

Relentless

Accountable

Passionate

Innovative

Diverse

Learn More

We are looking for talented, dedicated people wishing to contribute to our common vision of enhancing the health and well being of people worldwide.

Subscribe to the Chembio Mailing List